European Commission Approves Opzelura for Adults with Moderate Atopic Dermatitis After Inadequate Response to Standard Topical Therapies

The European Commission (EC) has approved Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adults whose disease is inadequately controlled with, or for whom treatment is inappropriate using, topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs). The approval expands treatment options for patients with persistent disease and establishes Opzelura as the first steroid-free topical Janus kinase (JAK) inhibitor approved in the European Union for atopic dermatitis.

The decision follows the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) positive opinion issued in June 2026 and represents Opzelura’s second approved indication in Europe, following its authorization for non-segmental vitiligo with facial involvement.

A Targeted JAK Inhibitor for Chronic Inflammatory Skin Disease

Opzelura contains ruxolitinib, a selective JAK1/JAK2 inhibitor formulated as a topical cream. By blocking JAK-mediated inflammatory signaling, the treatment reduces immune-driven skin inflammation responsible for eczema symptoms while avoiding corticosteroid exposure.

Atopic dermatitis is the most common form of eczema and affects up to 4% of adults worldwide. The chronic inflammatory disease causes persistent itching, skin lesions, disrupted sleep, and impaired quality of life. Although topical corticosteroids remain standard first-line therapy, many patients experience inadequate responses, intolerance, or treatment limitations with prolonged steroid use.

Phase 3b TRuE-AD4 Met Primary Endpoints and Demonstrated Sustained Disease Control

The EC approval is primarily supported by the Phase 3b TRuE-AD4 trial (NCT06238817), together with evidence from the Phase 3 TRuE-AD1 (NCT03745638) and TRuE-AD2 studies (NCT03745651).

TRuE-AD4 enrolled 241 adults with moderate atopic dermatitis involving 10% to 20% body surface area who had a documented inadequate response, intolerance, or contraindication to both topical corticosteroids and topical calcineurin inhibitors. Participants were randomized in a 2:1 ratio to receive twice-daily Opzelura or vehicle cream.

At Week 8, the study met both co-primary endpoints. A significantly greater proportion of patients treated with Opzelura achieved:

• EASI-75, representing at least a 75% improvement in Eczema Area and Severity Index scores.
• Investigator’s Global Assessment Treatment Success (IGA-TS), defined as clear or almost clear skin with at least a two-point improvement from baseline.

Clinical benefits extended beyond physician assessments. Patients reported itch improvement as early as Day 2, while mean affected body surface area declined from 15.1% at baseline to 2.5% by Week 8 and remained stable through Week 24.

Disease control was maintained during as-needed treatment, with 84.3% of eligible patients maintaining EASI-75 responses and 70.6% achieving IGA treatment success at Week 24. Clinically meaningful itch reduction, defined as at least a four-point improvement on the Itch Numeric Rating Scale (NRS4), was observed in 74.3% of patients at Week 8 and remained 64.7% at Week 24.

Quality-of-life outcomes also improved substantially. Mean Dermatology Life Quality Index (DLQI) scores declined from 19.3 to 4.3 with Opzelura compared with 19.1 to 10.7 in the vehicle group after eight weeks of treatment.

Favorable Safety Profile Supports Long-Term Management

Opzelura demonstrated a favorable tolerability profile throughout the 24-week study.

No serious infections, major adverse cardiovascular events, malignancies, or thromboses were reported during treatment. The most common treatment-emergent adverse events were upper respiratory tract infection (10.6%) and nasopharyngitis (6.3%), with no new safety signals identified.

These findings support intermittent, as-needed use after initial disease control, an important consideration for long-term management of chronic atopic dermatitis.

Experts Highlight an Additional Steroid-Free Treatment Option

Incyte Chief Executive Officer Bill Meury said the approval expands treatment options for adults with moderate atopic dermatitis across Europe and reinforces the company’s commitment to advancing therapies for inflammatory and autoimmune diseases.

Professor Andreas Wollenberg, Professor of Dermatology and Allergy at University Hospital Augsburg, noted that many patients continue to experience persistent symptoms despite existing topical therapies. He said the availability of a steroid-free topical JAK inhibitor provides a valuable option for patients who cannot adequately use topical corticosteroids or calcineurin inhibitors.

Regulatory Significance

The European Commission approval strengthens Opzelura’s position as a differentiated topical therapy within inflammatory dermatology. With approvals now covering both non-segmental vitiligo and moderate atopic dermatitis in Europe, Incyte continues expanding the clinical role of topical JAK inhibition. The positive TRuE clinical program provides a robust evidence base supporting sustained efficacy, rapid itch relief, improved quality of life, and long-term safety for adults requiring alternatives to conventional topical treatments.

Reference

Opzelura® (ruxolitinib) Cream Becomes First Steroid-Free Topical JAK Inhibitor Approved in the European Union for Adults with Moderate Atopic Dermatitis | Incyte